This year's World Alzheimer's Day campaign aims to address the stigma and discrimination while highlighting global efforts to ...

In the past two years, the U.S. Food and Drug Administration has approved two monoclonal antibody treatments to slow ...

Cambridge Vision Technology utilises AI-based technology to detect Alzheimer’s disease early on by using ocular biomarkers ...

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive ...

A new study helps explain why having ApoE4—the gene variant most closely linked to Alzheimer's disease—increases the risk of ...

The ALPS index effectively distinguishes individuals with SCD from those with normal cognition and is correlated with amyloid beta burden.

The plaque building is one component of Alzheimer's disease pathology, the release said. A hallmark of Alzheimer's is the ...

A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...

New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting ...

The scientists looked at two brain scans and found that areas with more amyloid-beta showed increased brain activity, with ...